MCE - Delayed Quote EUR

Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)

80.45 +1.00 (+1.26%)
At close: 5:36 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
829,509.00
829,509.00
817,698.00
648,677.00
419,961.00
Cost of Revenue
337,224.00
337,224.00
298,085.00
263,855.00
178,652.00
Gross Profit
492,285.00
492,285.00
519,613.00
384,822.00
241,309.00
Operating Expense
272,031.00
272,031.00
263,763.00
203,335.00
163,880.00
Operating Income
220,254.00
220,254.00
255,850.00
181,487.00
77,429.00
Net Non Operating Interest Income Expense
556.00
556.00
921.00
-837.00
-1,068.00
Pretax Income
220,408.00
220,408.00
257,967.00
182,628.00
72,581.00
Tax Provision
50,109.00
50,109.00
58,302.00
29,551.00
11,524.00
Net Income Common Stockholders
170,335.00
170,335.00
199,669.00
153,077.00
61,057.00
Diluted NI Available to Com Stockholders
170,335.00
170,335.00
199,669.00
153,077.00
61,057.00
Basic EPS
3.20
3.29
3.73
2.76
1.10
Diluted EPS
3.20
3.29
3.73
2.76
1.10
Basic Average Shares
53,192.00
51,842.35
53,466.00
55,404.00
55,386.00
Diluted Average Shares
53,192.00
51,842.35
53,466.00
55,404.00
55,386.00
Total Operating Income as Reported
220,254.00
220,254.00
255,848.00
181,392.00
74,651.00
Rent Expense Supplemental
2,462.00
2,462.00
3,470.00
839.00
327.00
Total Expenses
609,255.00
609,255.00
561,848.00
467,190.00
342,532.00
Net Income from Continuing & Discontinued Operation
170,335.00
170,335.00
199,669.00
153,077.00
61,057.00
Normalized Income
170,482.64
170,482.64
198,261.88
151,418.84
64,242.71
Interest Income
7.00
7.00
6.00
68.00
4.00
Interest Expense
667.00
667.00
606.00
669.00
806.00
Net Interest Income
556.00
556.00
921.00
-837.00
-1,068.00
EBIT
221,075.00
221,075.00
258,573.00
183,297.00
73,387.00
EBITDA
245,406.00
245,406.00
281,444.00
204,661.00
92,980.00
Reconciled Cost of Revenue
337,224.00
337,224.00
298,085.00
263,855.00
178,652.00
Reconciled Depreciation
24,331.00
24,331.00
22,871.00
21,364.00
19,593.00
Net Income from Continuing Operation Net Minority Interest
170,335.00
170,335.00
199,669.00
153,077.00
61,057.00
Total Unusual Items Excluding Goodwill
-191.00
-191.00
1,818.00
1,974.00
-3,788.00
Total Unusual Items
-191.00
-191.00
1,818.00
1,974.00
-3,788.00
Normalized EBITDA
245,597.00
245,597.00
279,626.00
202,687.00
96,768.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-43.36
-43.36
410.88
315.84
-602.29
12/31/2020 - 12/5/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ORY.MC Oryzon Genomics S.A.
2.0300
+2.53%
 
PHM.MC Pharma Mar, S.A.
27.60
+4.07%
 
PMRA.F Pharma Mar, S.A.
26.32
-1.79%
 
ABVX.PA ABIVAX Société Anonyme
15.18
+5.42%
 
PRTC.L PureTech Health plc
213.00
+3.65%
 
SER Serina Therapeutics, Inc.
10.00
+1.94%
 
CAMX.ST Camurus AB (publ)
483.20
+1.73%
 
SLRX Salarius Pharmaceuticals, Inc.
0.5200
+1.96%
 
IKNA Ikena Oncology, Inc.
1.4000
+7.69%
 
AURA Aura Biosciences, Inc.
7.29
+2.82%